A California-based biotechnology
company, International Stem Cell Corporation (OTCQB: ISCO) focuses its energies
on developing restorative medicine using stem cell technology. Its innovative
parthenogenesis technology uses human stem cells derived from unfertilized
oocytes (eggs), which helps the company avoid any ethical issues involving the
destruction of viable human embryos. ISCO also produces and markets cells and
growth media for therapeutic research worldwide through its subsidiary,
Lifeline Cell Technology. For even more revenue, the company’s other
subsidiary, Lifeline Skin Care, markets and sells a skin care line that
promises rejuvenation and beauty.
In December, Lifeline Skin Care
launched its Molecular Renewal Serum™, just in time for the holidays. This
product contains an impressive nano-compound that works with skin to replenish
elasticity and smoothness. During testing, the serum showed improvement in
skin’s resilience and a decrease in roughness without any negative side
effects. The serum also stimulates collagen production, which lends strength to
skin by regrowing dead skin cells.
That same month, ISCO announced
that it had entered a master clinical research agreement with Florey Institute
of Neuroscience and Mental Health, one of the world’s leading brain research
centers. The agreement cleared the way for scientists to conduct a Phase I/IIa
clinical trial studying the effects of human parthenogenetic stem cells in
people with Parkinson’s disease. Patients are to be enrolled during the first
quarter of 2016.
ISCO’s groundbreaking stem cells
are created by stimulating oocytes into dividing themselves into
histocompatible cells. The company strives to create immune matching cells, so
that people do not reject the treatment. So far, ISCO scientists have developed
the first line of stem cells that can be used as therapeutic cells for millions
of people with minimal rejection. The company also aligns itself with the
UniStemCell Bank, the first collection of non-embryonic stem cells, in the hopes
of increasing widespread use and scientific breakthroughs.
With the steady financial growth
of ISCO and its subsidiaries, the company hopes to continue making great
strides in regenerative techniques for eye, liver, and nervous system diseases.
For more information, visit
www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
Sign up for “The QualityStocks
Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment